New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
08:09 EDTNEPTNeptune Technologies obtains third U.S. patent on phospholipid compositions
Neptune Technologies & Bioressources announces that the U.S. Patent & Trademark has granted to Neptune a new continuation patent, U.S. Patent 8,383,675. This new patent claims the benefit of prior Neptune U.S. Patent Nos. 8,030,348 and 8,278,351. The '675 Patent contains a single claim directed to a capsule comprising an Antarctic krill oil extract comprising a phospholipid suitable for human consumption. This claim covers most, if not all, krill oil products presently sold in the U.S. market, as well as the pharmaceutical concentrates of Neptune's subsidiaries Acasti Pharma and NeuroBioPharm. Henri Harland, president and CEO of Neptune, commented; "This is not 'just another patent for Neptune.' It is part of Neptune's IP strategy, and it reinforces Neptune's continual effort to build its patent portfolio and defend its rights. Neptune's recent filing of a complaint with the United States International Trade Commission, as well as the issuance of this third composition patent in the United States, are part of Neptune's well thought and ongoing IP action plan."
News For NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
17:14 EDTNEPTNeptune Technologies and NeuroBioPharm announces arrangement agreement
Neptune Technologies & Bioressources and NeuroBioPharm, a subsidiary of Neptune, announce that they have entered into an arrangement agreement which will result in the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio. The Arrangement Agreement provides, amongst other things, that NeuroBio will amalgamate with a newly formed wholly-owned subsidiary of Neptune and that each shareholder of NeuroBio will receive, as applicable, (i) 0.046296296 share of Neptune for each Class A share of NeuroBio held, (ii) 0.185185185 share of Neptune for each Class B share of NeuroBio held, (iii) 0.092592593 share of Neptune for each Class G share of NeuroBio held, and (iv) 0.208333333 share of Neptune for each Class H share of NeuroBio held. An interim order of the Superior Court of Québec granted today provides for, among other things, the calling and holding of a special meeting of shareholders to consider the Arrangement.
17:12 EDTNEPTNeptune Technologies reports Q3 revenue $4.71M, consensus $5.60M.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use